Evidence map›Paper›PMID 38137692›Full record

ArticleJournal of clinical medicine2023

Death and Venous Thromboembolism Analyses among Hospitalized COVID-19-Positive Patients: A Multicenter Study.

Asma Alshahrani, Abdullah Almoahzieie, Hanan Alshareef, Buthinah B Alammash, Sarah Alhamidi, Abdulkarim M Meraya, Abdullah S Alshammari, Aziza Ajlan, Alnajla Alghofaili, Abdullah Alnassar and 9 more

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Factors Associated with Different Survival Functions in Anticoagulated Patients with Chronic Kidney Disease.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 13 institutions in 2 countries.

Asma AlshahraniDepartment of Clinical Pharmacy, Faculty of Pharmacy, King Khalid University, Abha 62529, Saudi Arabia.ORCID 0000-0002-2628-3622
Abdullah AlmoahzieiePharmaceutical Care Division, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia.
Hanan AlshareefDepartment of Pharmacy Practice, Faculty of Pharmacy, University of Tabuk, Tabuk 47512, Saudi Arabia.ORCID 0000-0002-1264-7229
Buthinah B AlammashDepartment of Pharmaceutical care services, King Fahad Hospital, Ministry of Health, AL Madinah Munawara 42351, Saudi Arabia.
Sarah AlhamidiPharmaceutical Care Division, Security Forces Hospital, Riyadh 11481, Saudi Arabia.
Abdulkarim M MerayaDepartment of Clinical Pharmacy, Pharmacy Practice Research, College of Pharmacy, Jazan University, Jazan 82722, Saudi Arabia.ORCID 0000-0002-6876-7270
Abdullah S AlshammariPharmaceutical Practice Department, College of Pharmacy, Umm Al-Qura University, Makkah 24382, Saudi Arabia.ORCID 0000-0002-9994-7266
Aziza AjlanPharmaceutical Care Division, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia.ORCID 0000-0002-5562-9928
Alnajla AlghofailiPharmaceutical Care Division, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia.
Abdullah AlnassarPharmaceutical Care Division, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia.
Nada AlshahraniDepartment of Internal Medicine, Prince Sultan Medical City, Riyadh 12624, Saudi Arabia.
Maram AldossariPharmaceutical Care Division, King Abdulaziz Medical City, Riyadh 11426, Saudi Arabia.
Turkiah AlkhaldiDepartment of Clinical Pharmacy, King Fahad Medical City, Riyadh 11525, Saudi Arabia.
Marwan J AlwazzehDepartment of Internal Medicine, King Fahd Hospital of the University, Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia.ORCID 0000-0002-4646-6717
Abdullah B AlmashoufDepartment of Internal Medicine, King Fahd Hospital of the University, Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia.
Feras A AlkuwaitiDepartment of Internal Medicine, King Fahd Hospital of the University, Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia.
Shrouq Hamed AlghamdiDepartment of Pharmacy, Prince Muhammad bin Abdualaziz Hospital, Ministry of Health, Riyadh 12769, Saudi Arabia.
Ohuod AlshehriDepartment of Clinical Pharmacy, Faculty of Pharmacy, King Khalid University, Abha 62529, Saudi Arabia.
Mostafa AliDepartment of Pharmacy Practice, Faculty of Pharmacy, University of Tabuk, Tabuk 47512, Saudi Arabia.ORCID 0000-0002-5851-5088
King Fahd Hospital of the University · SAKing Faisal Specialist Hospital & Research Centre · SAKing Khalid University · SAUniversity of Tabuk · SAAlfaisal University · SAJazan University · SAKing Abdulaziz Medical City · SAKing Fahad Hospital Jeddah · SAKing Fahd Medical City · SAPrince Mohammed bin Abdulaziz Hospital · SAPrince Sultan University · SASecurity Forces Hospital · SAUmm al-Qura University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCoagulation disorders are frequently encountered among patients infected with coronavirus disease 2019 (COVID-19), especially among admitted patients with more severe symptoms. This study aims to determine the mortality rate and incidence and risk factors for venous thromboembolism (VTE) in hospitalized patients with COVID-19.

methodsThis retrospective observational cohort study was conducted from March to July 2020 using a hospital database. All adult patients (>18 years old) with laboratory-confirmed COVID-19 were included. Laboratory data and the real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) for SARS-CoV-2 were obtained from medical records. The mortality rate and the incidence of VTE were established as study results. A multivariate logistic regression analysis was performed to identify predictors of thrombotic events.

resultsrA total of 1024 confirmed COVID-19 patients were treated, of whom 110 (10.7%) were deceased and 58 patients (5.7%) developed VTE. Death occurred more frequently in patients older than 50 years and those admitted to the intensive care unit (ICU, 95%) and who received mechanical ventilation (62.7%). Multivariate analysis revealed that cancer patients were two times more likely to have VTE (adjusted odds ratio = 2.614; 95% CI = (1.048-6.519);

conclusionsOne-tenth of hospitalized COVID-19 patients were deceased, and VTE was prevalent among patients with chronic conditions, such as cancer, despite anticoagulation therapy. Healthcare professionals should closely monitor individuals with a high risk of developing VTE to prevent unwanted complications.

Indexed as

coagulation disordersCOVID-19SARS-CoV-2venous thromboembolism

Identifiers

PMID38137692
PMCPMC10743652
OpenAlexW4389538125

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.